Document:

exv10w6

Exhibit 10.6

EXECUTION COPY

ADDITIONAL FUNDING AGREEMENT

     This ADDITIONAL FUNDING AGREEMENT (this “Agreement”) is entered into as of October 1,
2008, by and among OXiGENE, INC., a Delaware corporation (the “Company”), SYMPHONY ViDA
HOLDINGS LLC, a Delaware limited liability company (“Holdings”), SYMPHONY ViDA INVESTORS
LLC, a Delaware limited liability company (“Investors”), and SYMPHONY ViDA, INC., a
Delaware corporation (the “Symphony Collaboration”).

PRELIMINARY STATEMENT

     WHEREAS, the Company and Holdings have entered into a Technology License Agreement, dated as
of October 1, 2008, pursuant to which the Company has granted Holdings an exclusive license to the
use of certain intellectual property related to the Programs owned or controlled by the Company;

     WHEREAS, contemporaneously with the execution of this Agreement, the Company, Holdings and the
Symphony Collaboration are entering into a Novated and Restated Technology License Agreement,
pursuant to which, among other things, Holdings will assign by way of novation such license to the
Symphony Collaboration;

     WHEREAS, the Company and Holdings have entered into a Research and Development Agreement,
dated as of October 1, 2008, pursuant to which Holdings and the Company have agreed to develop the
Programs and to establish a Development Committee to oversee such development;

     WHEREAS, contemporaneously with the execution of this Agreement, the Company, Holdings and the
Symphony Collaboration are entering into an Amended and Restated Research and Development
Agreement, pursuant to which, among other things, Holdings will assign its rights and obligations
under the Research and Development Agreement to the Symphony Collaboration;

     WHEREAS, contemporaneously with the execution of this Agreement, Holdings, the Company, and
the Symphony Collaboration are entering into a Purchase Option Agreement (the “Purchase Option
Agreement”) pursuant to which, among other things, Holdings is granting to the Company an
option to purchase all of the equity securities of the Symphony Collaboration owned, or hereafter
acquired, by Holdings on the terms set forth in the Purchase Option Agreement;

     WHEREAS, Investors, through Holdings, agrees that it will make a single second capital
contribution (the “Additional Holdings Funding”) of up to $10,000,000 to the Symphony
Collaboration, on the Additional Closing Date (as defined herein), if required pursuant to the
terms hereof (the “Additional Holdings Funding Commitment”);

     WHEREAS, the Company agrees that it will issue shares of the Company Common Stock (the
“Additional Investment Shares”) having a value of up to $1,000,000 pursuant to the terms
hereof and the terms of the Stock and Warrant Purchase Agreement;

 

 

     WHEREAS, the Company desires to have the option to make expenditures with respect to the
Programs and the development thereof or payments to the Symphony Collaboration in respect thereof
(the “Optional Company Funding”) of up to $5,000,000 pursuant to the terms hereof;

     WHEREAS, the Company agrees that, upon the occurrence of certain events as described herein,
it will pay an aggregate amount of up to $15,000,000 (the “Company Payment Commitment”) to
the Symphony Collaboration; and

     WHEREAS, the Company, the Symphony Collaboration and Holdings have determined that it is in
each of its best interest to perform and comply with certain agreements relating to each of its
ongoing operations contained in this Agreement;

     NOW, THEREFORE, in consideration of the foregoing and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
(the “Parties”) agree as follows:

          1. Defined Terms. Terms not otherwise defined herein are used as defined in the
Purchase Option Agreement, including Annex A thereto.

          2. Required and Approved Funding; Optional Company Funding.

               (a) If, pursuant to Section 14 of the Development Committee Charter the Development
Committee determines that additional funds will be required to complete the development of the
Programs, the Development Committee shall deliver a notice to the Symphony Collaboration Board,
which notice shall (i) state that, pursuant to the Development Budget, additional funds will be
required to complete the development of the Programs and (ii) specify the Required Amount (as
defined therein).

               (b) Upon receipt of the notice specified above, the Symphony Collaboration Board shall approve
an amount in an increment of $1,000,000 to be funded (the “Approved Amount”) and notify the
Company of such amount.

               (c) Within five calendar days of receipt of notice from the Symphony Collaboration Board of
the Approved Amount, the Company shall provide irrevocable written notice to the Symphony
Collaboration of the amount of the Optional Company Funding that it agrees to make available to the
Symphony Collaboration in its sole discretion (such amount, which may be zero, the “Optional
Company Funding Amount”) before or on the earlier of (i) the 30th calendar day immediately
following the Balance Sheet Deficiency Date or (ii) the second anniversary of the Closing Date
(such date, the “Additional Closing Date”).

               (d) Subject to the limitations set forth in Section 3(c), the Company shall make the
Optional Company Funding Amount available by either (x) not invoicing the Symphony Collaboration
for expenditures under the Development Plan and Development Budget or (y) paying amounts to the
Symphony Collaboration in immediately available funds by wire transfer to the account designated by
the Symphony Collaboration; provided, that if the payment option under clause (x) above is
elected and

2

 

any portion of the Optional Company Funding Amount remains unpaid on the expiration of the
Term, such unpaid portion of the Optional Company Funding Amount shall be paid on the day the Term
expires pursuant to clause (y) above. The Company shall report to the Symphony Collaboration in
writing each month the amount, if any, of the Optional Company Funding Amount made available that
month and cumulatively since the Closing Date (which reports are subject to audit and adjustments
for any inaccuracies by the Company). In no event shall the Optional Company Funding Amount exceed
$5,000,000.

               (e) If the Company fails to notify the Symphony Collaboration of the Optional Company Funding
Amount within 5 calendar days of the receipt of notice of the Approved Amount, the Optional Company
Funding Amount shall be deemed to be $0 (zero dollars).

          3. Additional Holdings Funding.

               (a) The Symphony Collaboration Board shall determine the amount, if any, of the Approved
Amount that it will require Holdings to fund (the “Additional Holdings Payment Amount”),
taking into account the Optional Company Funding Amount; provided, that (x) the Additional
Holdings Payment Amount may be $0 (zero dollars); and (y) subject to Section 7 below, the
Additional Holdings Payment Amount shall not exceed $5,000,000. The Symphony Collaboration shall
notify Holdings and the Company of the Additional Holdings Payment Amount within 10 calendar days
of receipt of notice from the Company of the Optional Company Funding Amount. If no notice is
received by Holdings, then the Additional Holdings Payment Amount shall be deemed to be $0.

               (b) Subject to Sections 3(a) and 7, if the difference between the Approved
Amount and the Optional Company Funding Amount is less than or equal to $5,000,000, Holdings shall
be required to fund the entire difference, up to $5,000,000, between the Approved Amount and the
Optional Company Funding Amount.

               (c) If the difference between the Approved Amount and the Optional Company Funding Amount is
greater than $0 and the Additional Holdings Payment Amount is equal to $0, the Company’s
obligations to make all or any part of the Optional Company Funding Amount available to the
Symphony Collaboration shall immediately terminate.

               (d) Holdings shall pay to the Symphony Collaboration the Additional Holdings Payment Amount as
an additional capital contribution on the Additional Closing Date; provided, that in the
event that the Company elects to exercise the Purchase Option in accordance with Section 4
below, Holdings’ obligation to pay such amount shall be suspended until such time, if ever, that
the Company must pay the Company Payment Amount pursuant to Section 4 below after the
exercise of such election. In the event that the Purchase Option Closing Date occurs and Holdings
is paid in full all amounts owed to it under the Purchase Option Agreement, Holdings obligations
hereunder in respect of the Additional Holdings Payment Amount shall terminate.

3

 

          4. Company Payment Amount.

               (a) So long as the Additional Holdings Payment Amount is greater than $0 and Holdings has paid
such amount in full to the Symphony Collaboration, the Symphony Collaboration may require the
Company to pay to the Symphony Collaboration an amount (such amount, the “Company Payment
Amount”) equal to (x) the difference between the Company Payment Commitment and the Optional
Company Funding Amount, less (y) the aggregate amount of Discontinued Funds and payments received
by the Symphony Collaboration from the Company following the exercise of a Discontinuation Option
that are declared as dividends or otherwise distributed to Holdings pursuant to Section 8.1
of the Amended and Restated Research and Development Agreement; provided, that, subject to
Section 7 below, if the difference between the Approved Amount and the Optional Company
Funding Amount is greater than or equal to $5,000,000 and the Additional Holdings Payment Amount is
less than $5,000,000, the Company Payment Amount shall in no event be greater than the Additional
Holdings Payment Amount; provided further, that, subject to Section 7
below, the Company Payment Amount shall not exceed $10,000,000.

               (b) Such payment, if so required, shall be made within ten (10) Business Days of receipt of
written notice by the Symphony Collaboration of the Company Payment Amount (the date of such
payment, the “Company Payment Date”) and by either (or a combination of) (x) not invoicing
the Symphony Collaboration for expenditures under the Development Plan and Development Budget
incurred through the Company Payment Date (as notified in writing in reasonable detail by the
Company to the Symphony Collaboration which notice is subject to audit and adjustments for any
inaccuracies by the Company) or (y) paying amounts to the Symphony Collaboration in immediately
available funds by wire transfer to the account designated by the Symphony Collaboration;
provided, that in lieu of making such payment and so long as the Purchase Option Period has
not expired the Company may elect within such ten Business Day period to exercise the Purchase
Option pursuant to the terms of the Purchase Option Agreement and purchase Holdings’ interest in
the Symphony Collaboration in accordance with the Purchase Option Agreement; provided
further, that if the payment option under clause (x) above is elected and any portion of
the Company Payment Amount remains unpaid on the expiration of the Term, such unpaid portion of the
Company Payment Amount shall be paid on the day the Term expires pursuant to clause (y) above;
provided further, that if the Term has expired, the Company Payment Amount shall
only be paid pursuant to clause (y) above. In the event that the Purchase Option is exercised by
the Company but Holdings is not paid in full on a timely basis as required under the Purchase
Option Agreement, the Company shall on demand by the Symphony Collaboration pay in full the Company
Payment Amount in immediately available funds by wire transfer to the account designated by the
Symphony Collaboration.

          5. Company Common Stock Issuance Obligation.

               (a) On the Additional Closing Date, if the Additional Holdings Payment Amount is paid to the
Symphony Collaboration, the Company shall issue the Additional Investment Shares to Holdings in
accordance with Section 2.05 of the Stock

4

 

and Warrant Purchase Agreement; provided, that if the Additional Holdings Payment
Amount is less than $10,000,000, the number of Additional Investment Shares shall be
proportionately reduced.

               (b) If stockholder approval for the issuance of such Additional Investment Shares is required
but not obtained, the Company shall issue to the Investors, through Holdings, a warrant (the
“Additional Investment Warrant”) in accordance with Section 2.05 of the Stock and
Warrant Purchase Agreement.

     6. Company Payment Obligation.

               (a) The Company agrees that, on the terms and conditions set forth herein, it will pay to the
Symphony Collaboration the Company Payment Amount in an amount not to exceed the Company Payment
Commitment.

               (b) In the event that a Bankruptcy Event occurs during the Term with respect to the Company
and subject to Section 7 below, the Company agrees to pay to the Symphony Collaboration an
amount equal to the difference, if any, between $10,000,000 and the aggregate amount of the sum of
(x) the Optional Company Funding Amounts actually made available or paid to the Symphony
Collaboration and (y) all Company Payment Amounts actually paid by the Company pursuant to
Section 4 above, and such amount shall be immediately due and payable upon the occurrence
of such Bankruptcy Event.

               (c) The Company hereby waives all right to set off amounts owing under Section 4 or
this Section 6 against any amounts owing by Holdings or the Symphony Collaboration to the
Company under the Operative Documents, unless otherwise agreed.

               (d) Holdings, Investors and the Symphony Collaboration shall be entitled to exercise any and
all remedies at law or in equity to enforce the Company’s obligations hereunder.

     7. Adjustment to Certain Funding Terms. Notwithstanding anything contained herein to
the contrary, Holdings may, at its sole option and upon written notice to the Company,
proportionately increase (i) all amounts set at $5,000,000 in Sections 3(a), 3(b)
and 4(a) to up to $10,000,000 and (ii) all amounts set at $10,000,000 in Sections
4(a) and 6(b) to up to $15,000,000.

     8. Notice. Any notice, request, demand, waiver, consent, approval or other
communication which is required or permitted to be given to any Party shall be in writing addressed
to the Party at its address set forth below and shall be deemed given (i) when delivered to the
Party personally, (ii) if sent to the Party by facsimile transmission (promptly followed by a
hard-copy delivered in accordance with this Section 8), when the transmitting Party obtains
written proof of transmission and receipt; provided, however, that notwithstanding the foregoing,
any communication sent by facsimile transmission after 5:00 PM (receiving Party’s time) or not on a
Business Day shall not be deemed

5

 

received until the next Business Day, (iii) when delivered by next Business Day delivery by a
nationally recognized courier service, or (iv) if sent by registered or certified mail, when
received, provided postage and registration or certification fees are prepaid and delivery is
confirmed by a return receipt:

The Company:

OXiGENE, Inc.

230 Third Avenue

Waltham, MA 02451

Attn: Chief Executive Officer

Facsimile: (781) 547-6800

The Symphony Collaboration:

Symphony ViDA, Inc.

7361 Calhoun Place, Suite 325

Rockville, MD 20855

Attn: Charles W. Finn, Ph.D.

Facsimile: (301) 762-6154

Holdings:

Symphony ViDA Holdings LLC

7361 Calhoun Place, Suite 325

Rockville, MD 20855

Attn: Robert L. Smith, Jr.

Facsimile: (301) 762-6154

with copies to:

Symphony Capital Partners, L.P.

875 Third Avenue, 18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

and

Symphony Strategic Partners, LLC

875 Third Avenue, 18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

Investors:

6

 

Symphony ViDA Investors LLC

875 Third Avenue, 18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

or to such other address as such Party may from time to time specify by notice given in the manner
provided herein to each other Party entitled to receive notice hereunder.

          9. Governing Law; Consent to Jurisdiction and Service of Process.

               (a) This Agreement shall be governed by, and construed in accordance with, the laws of the
State of New York; except to the extent that this Agreement pertains to the internal governance of
the Symphony Collaboration, the Company or Holdings, and to such extent this Agreement shall be
governed and construed in accordance with the laws of the State of Delaware.

               (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its
property, to the nonexclusive jurisdiction of any New York State court, any Delaware State court or
federal court of the United States of America sitting in the City of New York, Borough of Manhattan
or Wilmington, Delaware, and any appellate court from any jurisdiction thereof, in any action or
proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any
judgment, and each of the Parties hereby irrevocably and unconditionally agrees that all claims in
respect of any such action or proceeding may be heard and determined in any such New York State
court or any such Delaware state court or, to the fullest extent permitted by law, in such federal
court. Each of the Parties agrees that a final judgment in any such action or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by law. Nothing in this Agreement shall affect any right that any Party may
otherwise have to bring any action or proceeding relating to this Agreement.

               (c) Each of the Parties irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection that it may now or hereafter have to the laying of
venue of any suit, action or proceeding arising out of or relating to this Agreement in any
New York State or federal court, or any Delaware State or federal court. Each of the Parties
hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient
forum to the maintenance of such action or proceeding in any such court. Each of the Parties
hereby consents to service of process by mail.

          10. Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ALL RIGHT TO
TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR
OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT.

7

 

          11. Entire Agreement. This Agreement (including any Annexes, Schedules, Exhibits or
other attachments hereto) constitutes the entire agreement between the Parties with respect to the
matters covered hereby and supersedes all prior and contemporaneous agreements, correspondence,
discussion, and understanding with respect to such matters between the Parties, excluding the
Operative Documents.

          12. Amendment; Successors; Counterparts.

               (a) The terms of this Agreement shall not be altered, modified, amended, waived or
supplemented in any manner whatsoever except by a written instrument signed by each of the Parties.

               (b) Nothing expressed or implied herein is intended or shall be construed to confer upon or to
give to any Person, other than the Parties, any right, remedy or claim under or by reason of this
Agreement or of any term, covenant or condition hereof, and all the terms, covenants, conditions,
promises and agreements contained herein shall be for the sole and exclusive benefit of the Parties
and their successors and permitted assigns.

               (c) This Agreement may be executed in one or more counterparts, each of which, when executed,
shall be deemed an original but all of which, taken together, shall constitute one and the same
Agreement.

          13. Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any rule of law or public policy, all other conditions
and provisions of this Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated hereby is not affected in a manner
materially adverse to either party. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible
in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the
extent possible.

[SIGNATURES FOLLOW ON NEXT PAGE]

8

 

     IN WITNESS WHEREOF, each of the undersigned has executed and delivered this Agreement, or has
caused this Agreement to be executed and delivered by a duly authorized officer, on the day and
year first above written.

	 	 	 	 	 
	 	OXiGENE, INC.

 	 
	 	By:  	/s/ John A. Kollins
 	 
	 	 	Name:  	John A. Kollins 	 
	 	 	Title:  	Chief Operating Officer 	 
	 
	 	SYMPHONY ViDA, INC.

 	 
	 	By:  	                     /s/ Mark Kessel
 	 
	 	 	Name:  	Mark Kessel 	 
	 	 	Title:  	Chairman of the Board 	 
	 

[Signature Page to Additional Funding Agreement]

 

	 	 	 	 	 	 	 
	 	 	SYMPHONY ViDA HOLDINGS LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony Capital Partners, L.P., 

its Manager	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony Capital GP, L.P., 

its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony GP, LLC,

its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Mark Kessel	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Mark Kessel

Title: Managing Member	 	 
	 
	 	 	 	 	 	 
	 	 	SYMPHONY ViDA INVESTORS LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony Capital Partners, L.P., 

its Manager	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony Capital GP, L.P., 

its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony GP, LLC,

its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Mark Kessel	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Mark Kessel	 	 
	 

	 	 	 	Title: Managing Member	 	 

[Signature Page to Additional Funding Agreement]exv10w7

Exhibit 10.7

AMENDMENT NO. 1 TO

STOCKHOLDER RIGHTS AGREEMENT

     This Amendment No. 1 to Stockholder Rights Agreement (the “Amendment”), dated as of October 1,
2008, by and between OXiGENE, Inc., a Delaware corporation (the “Company”), and American Stock
Transfer & Trust Company (the “Rights Agent”), amends that certain Stockholder Rights Agreement,
dated as of March 24, 2005, between the Company and the Rights Agent (the “Agreement”).

     WHEREAS, the parties desire to amend the Agreement, pursuant to Section 27 thereof, in
connection with the transactions described in and contemplated by (i) that certain Stock and
Warrant Purchase Agreement by and between the Company and Symphony ViDA Holdings LLC (“Symphony”),
dated as of even date herewith; (ii) that certain Novated and Restated Technology License Agreement
by and between the Company, Symphony ViDA, Inc. and Symphony, dated as of even date herewith; and
(iii) that certain Purchase Option Agreement by and between the Company and Symphony, dated as of
even date herewith.

     NOW THEREFORE, the parties hereby agree as follows:

     1. Definition of “Acquiring Person.” The definition of “Acquiring Person” as set
forth in Section 1(a) of the Agreement is hereby amended by adding the following to the end
thereof:

     “Notwithstanding anything herein to the contrary, none of Symphony ViDA Holdings LLC, Symphony
Capital LLC, Symphony Capital Partners, L.P., Symphony Strategic Partners, LLC or their Affiliates
shall be deemed to be an Acquiring Person solely by virtue of the transactions described in and
contemplated by (i) the Stock and Warrant Purchase Agreement by and between the Company and
Symphony ViDA Holdings LLC, dated as of October 1, 2008 (the “Symphony Purchase Agreement”), (ii)
the Novated and Restated Technology License Agreement by and between the Company, Symphony ViDA,
Inc. and Symphony ViDA Holdings, LLC, dated as of

 

 

October 1, 2008 (“Technology License Agreement”), and (iii) the Purchase Option Agreement by and
between the Company and Symphony, dated as of October 1, 2008 (the “Purchase Option Agreement”, and
together with the Symphony Purchase Agreement and the Technology License Agreement, the “Symphony
Operative Documents”), including but not limited to, where applicable, the acquisition of Common
Shares by such persons or entities pursuant to any of the Symphony Operative Documents.

     2. Definition of “Stock Acquisition Date.” The definition of “Stock Acquisition Date”
as set forth in Section 1(hh) of the Agreement is hereby amended by adding the following to the end
thereof:

     “Notwithstanding anything herein to the contrary, the execution, delivery and performance of
the Symphony Operative Documents and the transactions described and contemplated therein shall not
be deemed, by itself, to constitute or lead to a Stock Acquisition Date under this Agreement.”

     3. Definition of “Distribution Date.” The definition of “Distribution Date” as set
forth in Section 3(a) of the Agreement is hereby amended by adding the following to the end
thereof:

     “Notwithstanding anything herein to the contrary, the execution, delivery and performance of
the Symphony Operative Documents and the transactions described and contemplated therein shall not
be deemed, by itself, to constitute or lead to a Distribution Date under this Agreement.”

     4. Ratification. The parties hereby ratify and confirm in all respects the Agreement,
as amended by this Amendment.

     5. Governing Law. This Amendment shall be deemed to be a contract made under the laws
of the State of Delaware and for all purposes shall be governed by and construed in accordance with
the laws of such State applicable to contracts to be made and performed entirely within such State.

 

 

     6. Counterparts. This Amendment may be executed in any number of
counterparts and each of such counterparts shall for all purposes be deemed to be an original, and
all such counterparts shall together constitute but one and the same instrument.

     7. Descriptive Headings. Descriptive headings of the several Sections of
this Amendment are inserted for convenience only and shall not control or affect the meaning or
construction of any of the provisions hereof.

 

 

     IN WITNESS WHEREOF, the parties have entered into this First Amendment to Stockholder Rights
Agreement as of the date first stated above.

	 	 	 	 	 
	 	OXiGENE, INC.

 	 
	 	By:  	/s/ James B. Murphy
 	 
	 	 	Name:  	James B. Murphy 	 
	 	 	Title:  	Vice President and Chief Financial Officer 	 
	 
	 	AMERICAN STOCK TRANSFER & TRUST COMPANY

 	 
	 	By:  	/s/ Paula Caropolli
 	 
	 	 	Name:  	Paula Caropolli 	 
	 	 	Title:  	Vice President 	 
	 

[Signature Page to Amendment No. 1 to Stockholders’ Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]